CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Argenx's Efgartigimod Meets Primary Endpoint in Phase 3 Autoimmune Myositis Trial

By Public Technologies
  • argenx reported its Phase 3 ALKIVIA trial of efgartigimod met primary and key secondary endpoints in the combined autoimmune myositis population.
  • Immune-mediated necrotizing myopathy (IMNM) patients showed significant, sustained improvement versus placebo, supporting a potential first treatment for the condition.
  • A US filing for IMNM is planned by the end of 2026, supported by FDA Breakthrough Therapy Designation.
  • Dermatomyositis patients showed clinically meaningful improvement, but results did not reach statistical significance in this smaller group.
  • Results will be presented at ACR Convergence on November 11, 2026, from 9:15-9:30 a.m. ET.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611071001PRIMZONEFULLFEED1001302375) on November 07, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.